

Top 10 Things to Know About the Older Patient With HIV Infection

Howard Libman, MD

Professor of Medicine, Emeritus
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

IAS-USA

Learning Objectives

After attending this presentation, learners will be able to:

- Identify epidemiologic characteristics of the older HIV-infected patient
- Define the impact of HIV infection on the normal aging process and the development of comorbidities
- Describe specific HIV comorbidities with focus on coronary artery disease, its predisposing conditions, and premature bone loss
- Explain changing mortality patterns in the modern era of antiretroviral therapy

Slide 3 of 45

Which of the following statements about HIV-infected patients over 50 years of age is false?

1. They present at an earlier stage of disease.
2. They constitute 45% of HIV-infected patients.
3. They are at increased risk of neurocognitive impairment compared to general population.
4. They develop certain malignancies earlier than the general population.
5. They are more adherent to medical therapy.

Slide 4 of 45


HIV Epidemiology in Older Adult

- Since the 1980s, the percentage of HIV-infected patients over the age of 50 has gradually increased
- In 2015, 17% of newly diagnosed cases of HIV infection were in adults ≥ 50 years old with many having AIDS
- African Americans accounted for 43% of cases, whites for 36% of cases, and Hispanics/Latinos for 17% of cases
- In 2014, approximately 45% of HIV-infected persons in the US were ≥ 50 years old, 27% were ≥ 55 years old, and 6% were ≥ 65 years old
- MSM is the most common mode of transmission in older men, and heterosexual contact is the most common mode in older women

<http://www.cdc.gov/hiv/group/age/olderamericans/index.html>

Slide 5 of 45


New HIV Diagnoses by Age United States, 2015



Slide 6 of 45

<http://www.cdc.gov/hiv/group/age/olderamericans/index.html>

People Living with HIV by Age United States, 2014



Slide 7 of 45


<http://www.cdc.gov/hiv/group/age/olderamericans/index.html>

Issue 1

HIV infection, even when controlled, is associated with chronic immune activation that is superimposed upon immunologic senescence in the older adult

Slide 8 of 45

The Effect of Normal Aging on Health



Slide 9 of 45

Taffer GE. Normal Aging. UpToDate. Wolters Kluwer Health. 2014.


Issue 2

Older persons may be diagnosed later and have more advanced HIV infection at presentation

Slide 10 of 45

Issue 3

There is a less robust immunologic response to antiretroviral therapy in this population



Slide 11 of 45

Immunologic Response to ART


- Among 12,196 treatment-naïve patients in NA-ACCORD who initiated ART (observational cohort), immunologic response after 24 months of therapy decreased with increasing age starting at 40, but there was no effect on viral suppression
- A prospective study that evaluated treatment outcomes in 3,015 patients (401 of whom were over age 50) found that, despite better virologic control, clinical progression to an AIDS-defining diagnosis was higher (HR 1.52; 95% CI 1.2-2.0)

Althoff KN, Justice AC, Gange SJ et al. AIDS 2010;24:2469.
Grabar S, Kousignian I, Sobel A et al. AIDS 2004;18:2029.

Slide 12 of 45

Issue 4

In general, older HIV-infected patients have better medication adherence but an increased risk of drug toxicity



Slide 13 of 45

Medication Adherence

- Literature has reported up to 95% adherence in older HIV-infected patients
- In a recent meta-analysis, older age reduced the risk for non-adherence by 27% (RR 0.72; CI 0.64-0.82)
- Those studies assessing short-term and long-term non-adherence showed a significant reduction in both groups (RR 0.75; CI 0.64-0.87 and RR 0.65; CI 0.50-0.85, respectively)

Ghidei L, Simone MJ, Salow MJ et al. *Drugs Aging* 2013;30:809.

Slide 14 of 45

Drug Toxicity

- A higher rate of adverse events (64% vs. 35%) on protease inhibitors was reported in patients older than 60 compared to those under 40
- Another study of 508 treatment-naïve patients found that regimen changes due to toxicity were associated with increasing age
- May be from age-related decrease in renal and hepatic function, decrease in serum albumin level, and changes in cytochrome p450 enzyme system

Knobel H, Guelar A, Valdecillo G et al. *AIDS* 2001;15:1591.
Lodwick RK, Smith CJ, Youle M et al. *AIDS* 2008;22:1039.


Slide 15 of 45

Issue 5

HIV-infected patients accumulate “age-related” diseases at a younger chronological age

Hypothesis is that increased immune activation and long-term chronic inflammation contribute to premature aging in this population

Slide 16 of 45





Chronic Complications by Age and HIV Status

- Retrospective analysis of HIV-infected outpatients compared to seronegative persons (case-control study) from 2002 through 2009
- Examined cardiovascular disease, hypertension, diabetes mellitus, bone fractures, and renal failure
- Independent predictors of polypathology ($p < 0.001$) included older age (OR 1.11), male gender (OR 1.77), CD4 nadir below 200 (OR 4.46), and duration of antiretroviral therapy (OR 1.01)

Guaraldi G, Orlando G, Zona G et al. Clin Infect Dis 2011;53:1120.

Slide 18 of 45





Issue 6

Incidence of CAD is higher than that in HIV-negative patients matched for age and gender

CAD risk calculator results need to be interpreted in context of increased risk in the HIV-infected population

Slide 21 of 45

HIV infection has been associated with the following increased percentage risk of acute myocardial infarction beyond that explained by recognized risk factors:

1. 10 percent
2. 20 percent
3. 30 percent
4. 40 percent
5. 50 percent or more

Slide 22 of 45

HIV Infection and Coronary Artery Disease (1)

- Incidence of CAD is higher than that in HIV-negative patients matched for age and gender
- Studies have demonstrated an increase in subclinical atherosclerosis (eg, CMI thickness) and clinical endpoints (eg, acute MI)
- HIV infection is associated with increased soluble and cellular markers of inflammation, endothelial dysfunction, and altered coagulation, all of which have been shown to contribute to cardiovascular disease

Slide 23 of 45

HIV Infection and Coronary Artery Disease (2)

- Degree to which HIV infection itself, antiretroviral therapy, and other risks contribute to increased risk in this population is unknown
- High prevalence of traditional risk factors in this population
- Protease inhibitor class appears to be associated with higher risk of CAD; some data suggesting abacavir and efavirenz may also increase risk
- Discontinuation of ART is associated with higher risk of CAD

Slide 24 of 45

The Risk of Coronary Artery Disease in HIV-infected Patients

Table 2. Rates of AMI by HIV Status and Age Group*

	Age Group, y						
Status	<30	30-39	40-49	50-59	60-69	70-79	≥80
Uninfected							
No. of participants	1175	6703	21 666	19 805	4039	1103	140
No. of AMI events	0	10	184	210	66	30	14
AMI rates per 1000 person-years (95% CI)	---	0.3 (0.2-0.5)	1.5 (1.3-1.7)	2.2 (1.9-2.5)	3.3 (2.8-4.2)	6.7 (4.9-9.2)	21.5 (12.7-35.4)
HIV-infected							
No. of participants	725	2640	10 575	9042	2995	957	56
No. of AMI events	0	13	105	171	46	25	3
AMI rates per 1000 person-years (95% CI)	---	0.7 (0.4-1.2)	3.0 (2.6-3.5)	5.9 (5.0-6.7)	5.6 (4.7-6.7)	10.5 (7.4-14.7)	13.5 (4.3-42.3)
Incidence rate ratio (95% CI)	---	0.19 (0.09-0.39)	1.34 (1.04-1.73)	1.90 (1.47-2.51)	1.50 (1.03-2.16)	1.50 (0.9-2.5)	---

Abbreviations: AMI, acute myocardial infarction; HIV, human immunodeficiency virus.
*Age groups indicate that a rate was not calculated because there were 0 events.

Slide 25 of 45

Freiberg MS, Chang CC, Kuller LH et al. JAMA Intern Med 2013;173:614.

Traditional Risk Factors for Atherosclerosis (2)

- **Hyperlipidemia:** Simvastatin and lovastatin are contraindicated with protease inhibitors and cobicistat; atorvastatin, rosuvastatin, and pitavastatin can be used as alternatives; in this setting, it is prudent to start with low dose of drug and monitor for toxicity
- **Cigarette Smoking:** HIV-infected patients are more likely to smoke and less likely to quit compared to the general population (Ann Intern Med 2015); HIV-infected smokers lose more life-years to smoking than to HIV-related conditions (Clin Infect Dis 2013); no important drug interactions

Slide 29 of 45

Issue 7

HIV infection and its treatment and comorbidities have been associated with premature bone loss

Slide 30 of 45

Premature Bone Loss (1)

- Osteopenia, osteoporosis, and pathological fractures have been described
- Osteopenia is generally asymptomatic, although patients with lower T scores (-1.0 to -2.5) may be at increased risk for fracture
- Osteoporosis may present with fractures of vertebrae, forearms, or hips
- HIV infection itself, TDF, protease inhibitors, alterations in vitamin D metabolism, and lactic acidemia related to older NRTI drugs may be contributing factors to premature bone loss


Slide 31 of 45

Premature Bone Loss (2)

- Immobility, cigarette smoking, excessive alcohol use, chronic renal disease, hypogonadism, hyperparathyroidism, hyperthyroidism, and steroid use accentuate bone loss
- Optimal use of bone densitometry as screening test in this population is uncertain; HIVMA advises baseline in postmenopausal women and men ≥ 50 years of age
- Calcium and vitamin D should be given in high-risk patients; regular exercise and smoking cessation should be advised

Slide 32 of 45


Antiretroviral Exposure and Risk of Osteoporotic Fractures



Slide 33 of 45

Bedino R, Maalouf NM, Zhang S et al. AIDS 2012;26:825.

Effect of TDF Exposure on Risk of Any Fracture and Osteoporotic Fractures



Slide 34 of 45

Borges AH, Hoy J, Florence E et al. Clin Infect Dis 2017;64:1413.

Issue 8

Increasing age may be a risk factor for HIV-associated neurocognitive dysfunction, although studies examining this issue are limited

Slide 35 of 45

Neurocognitive Dysfunction

- Longitudinal study comparing 106 HIV-infected patients over 50 years of age to 96 patients between 20-39 years of age showed a three-fold higher risk of dementia on multivariate analysis
- Study adjusted for race, education, depression, substance abuse, ART, CD4 count, and viral load
- Depression appears to be more common in older HIV-infected persons compared to seronegative age-matched controls

Valcour V, Shikuma C, Shiramizu B et al. *Neurology* 2004;63:822.
Applebaum AB, Brennan M. Mental Health and Depression, in: *Older Adults with HIV: An In-Depth Examination of an Emerging Population*. New York: Nova Publishers, 2009.

Slide 36 of 45

Issue 9

Lung, hepatic, and anal cancers occur at a younger age in HIV-infected adults compared to seronegative persons

Slide 37 of 45

Malignancies

- Observational studies suggest that lung, hepatic, and anal cancers occur at younger age in HIV-infected adults compared to seronegative persons
- Using 15 HIV and cancer registry databases in the US, including 212,055 persons with AIDS, the age of diagnosis of non-AIDS-defining cancers was examined
- Only lung and anal cancers were seen in AIDS patients at younger age (median 50 years old vs. 54; $p < 0.001$) than expected

Slide 38 of 45

Shiels MS, Pfeiffer RM, Engels EA. Ann Intern Med 2010;153:452.

Which of the following statements regarding mortality in the modern era of ART is false?

1. The overall mortality rate in HIV-infected adults has declined over the past two decades.
2. An increasing percentage of causes of death are related to non-AIDS-defining conditions.
3. The highest percentage of deaths in HIV-infected adults is in the 25-34 age group.
4. Life expectancy of a 20-year-old person recently diagnosed with HIV infection has been modeled to be similar to that of the general population.


Slide 39 of 45

Issue 10

Mortality in HIV-infected persons has fallen substantially over past two decades with non-AIDS-related conditions now accounting for the majority of deaths

Slide 40 of 45

Trends in Annual Rates of Death due to HIV Infection by Age Group, 1987–2014—United States



Note. For comparison with data for 1989 and later years, data for 1987–1988 were modified to account for K2D-10 (in detection of K2D-Probe).



Slide 41 of 45


Mortality Trends

- In the D:A:D study, 3,909 deaths occurred among 49,731 subjects followed from 1999 through 2011
- Crude mortality rate of 12.7 per 1000 person-years
- AIDS-related causes were responsible for 29% of deaths, non-AIDS-related cancers for 15%, liver disease for 13%, and cardiovascular disease for 11%
- Deaths attributable to AIDS-related events decreased from 34% to 22%
- Proportion attributable to non-AIDS-defining malignancies increased from 9% to 23%

Smith CJ, Ryom L, Weber R et al. Lancet 2014;384:241.

Slide 42 of 45

Trends in the Percentage Distribution of Deaths due to HIV Infection by Age Group, United States, 1987-2014




Note. For comparison with data for 1989 and later years, data for 1987–1988 were modified to account for K2D-10 (in detection of K2D-Probe).



Slide 43 of 45

Mid-point Life Expectancy Estimates at Age 20 Years in Three Calendar Periods, Overall and by Sociodemographic Characteristics, 2000–2007



Slide 44 of 45 Samji H, Cescon A, Hogg RS et al. 2013; PLOS ONE. <https://doi.org/10.1371/journal.pone.0081355>

Question-and-Answer

IAS-USA

Top 10 Things to Know About the Older Patient With HIV Infection

Howard Libman, MD

SUGGESTED READINGS

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;58(1):e1-34.

Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. *AIDS*. 2012;26:825-831.

Borges AH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. *Clin Infect Dis*. 2017;64(10):1413-1421.

Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013;173(8):614-622.

Institute of Medicine of the National Academies. HIV screening and access to care: exploring the impact of policies on access to and provision of HIV care. <http://iom.edu/Reports/2011/HIV-Screening-and-Access-to-Care-Exploring-the-Impact-of-Policies-on-Access-to-and-Provision-of-HIV-Care.aspx>. Accessed on June 10, 2013.

Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEHIV cohort study. *Clin Infect Dis*. 2014;59(12):1787-1797.

Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation*. 2018;138(11):1100-1112.

Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. *Ann Intern Med*. 2010;153(7):452-460.

Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014;384(9939):241-248.

The National Academies of Sciences EaM. *HIV Screening and Access to Care: Exploring the Impact of Policies on Access to and Provision of HIV Care*. The National Academies Press, 2011.